ArticleFrontiers in medicine2021
Extensively Drug-Resistant Hypervirulent
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Prevalence and clonal diversity of carbapenem-resistant Klebsiella pneumoniae causing neonatal infections: A systematic review of 128 articles across 30 countries.PLoS medicine · 2023Pooled it
- Review
- Article
- Five-Year Trends in Multidrug- and Extensively Drug-Resistant Enterobacterales Causing Pediatric Urinary Infections in Southern Türkiye: A Surveillance Report.The Eurasian journal of medicine · 2026Article
- Hybrid plasmids: genetic diversity and hypervirulent phenotype ofFrontiers in microbiology · 2026Article
- The dual threat of hypervirulent and multidrug-resistantFrontiers in microbiology · 2026Review
- Multiplex PCR assay for the rapid detection ofJournal of medical microbiology · 2025Article
- Genotypic diversity and virulence factors of Klebsiella pneumoniae in a North Indian tertiary care hospital.BMC infectious diseases · 2024Article
- Article
- Characterization of blaOXA-232 carrying carbapenem-resistant Klebsiella pneumoniae (CRKP) & their expression profiles under selective carbapenem pressure: An in-depth study from India.The Indian journal of medical research · 2024Article
- Article
- Extensively and multidrug-resistant bacterial strains: case studies of antibiotics resistance.Frontiers in microbiology · 2024Review
- Hospital-acquired infections due to carbapenem-resistantThe Indian journal of medical research · 2023Article
- Outbreak report of polymyxin-carbapenem-resistant Klebsiella pneumoniae causing untreatable infections evidenced by synergy tests and bacterial genomes.Scientific reports · 2023Article
- Large-scale genomic analysis of global Klebsiella pneumoniae plasmids reveals multiple simultaneous clusters of carbapenem-resistant hypervirulent strains.Genome medicine · 2023Article
- Molecular typing methods & resistance mechanisms of MDRAIMS microbiology · 2023Review
- Occurrence and Genomic Characteristics of HypervirulentInfection and drug resistance · 2023Article
- Pyogenic spondylitis caused by Klebsiella pneumoniae: should the possibility of hypervirulent Klebsiella pneumoniae be considered?BMC infectious diseases · 2022Article
- Epidemiology and clinical characteristics of infection/colonization due to carbapenemase-producing Enterobacterales in neonatal patients.BMC microbiology · 2022Article
- Comparative in silico characterization of Klebsiella pneumoniae hypervirulent plasmids and their antimicrobial resistance genes.Annals of clinical microbiology and antimicrobials · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent emergence of multidrug-resistant (MDR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.